Last reviewed 2026-04-23 · How we verify

HCP0605

HCP0605 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.

HCP0605 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein. Used for Castration-resistant prostate cancer (CRPC), Androgen receptor-positive breast cancer.

At a glance

Mechanism of action

HCP0605 works by binding to the androgen receptor and recruiting it for proteasomal degradation, thereby eliminating both the protein and its transcriptional activity. This mechanism differs from traditional androgen receptor antagonists by completely removing the receptor rather than simply blocking its function, potentially overcoming resistance mechanisms. This approach is designed to provide enhanced efficacy in androgen receptor-driven cancers.

Approved indications

• Castration-resistant prostate cancer (CRPC)
• Androgen receptor-positive breast cancer

Common side effects

• Fatigue
• Nausea
• Diarrhea
• Rash

Key clinical trials

• Pharmacokinetics of HCP1401 and Co-administration of HCP0605, HGP1405 in Healthy Male Volunteers (PHASE1)
• Pharmacokinetics of HCP1305 and Co-administration of HCP0605, HGP0816 in Healthy Male Volunteers (PHASE1)
• A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605 (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HCP0605 CI brief — competitive landscape report
• HCP0605 updates RSS · CI watch RSS
• Hanmi Pharmaceutical Company Limited portfolio CI